XML 84 R73.htm IDEA: XBRL DOCUMENT v3.20.2
Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2018
USD ($)
Jul. 31, 2018
USD ($)
day
$ / shares
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
Debt Instrument [Line Items]                
Proceeds from long-term debt, net of issuance costs         $ 0 $ 376,000    
Deferred income taxes         136,000 981,000    
Accrued interest     $ 3,500,000   3,500,000      
Long-term debt     223,313,000   223,313,000   $ 217,991,000  
Convertible debt                
Debt Instrument [Line Items]                
Long-term debt     219,341,000   219,341,000   213,771,000  
Notes payable                
Debt Instrument [Line Items]                
Long-term debt     3,868,000   3,868,000   4,089,000  
Precigen ActoBio Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP                
Debt Instrument [Line Items]                
Debt instrument, interest rate, stated percentage               3.00%
Interest expense     234,000 $ 228,000 469,000 $ 453,000    
Long-term debt     $ 31,680,000   $ 31,680,000      
Trans Ova Genetics, LC | Notes payable | American State Bank                
Debt Instrument [Line Items]                
Debt instrument, interest rate, stated percentage     3.95%   3.95%      
Long-term debt     $ 3,868,000   $ 3,868,000      
Debt instrument, periodic payment         39,000      
Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio Inc.                
Debt Instrument [Line Items]                
Aggregate principal amount               $ 30,000,000
3.5% Convertible Notes Due 2023                
Debt Instrument [Line Items]                
Aggregate principal amount   $ 200,000,000 $ 200,000,000   $ 200,000,000      
Proceeds from long-term debt, net of issuance costs   193,958,000            
Debt issuance costs   $ 6,042,000            
Debt instrument, interest rate, stated percentage   3.50% 3.50%   3.50%      
Conversion rate   58.6622            
Principal amount used in conversion   $ 1,000            
Conversion price (in usd per share) | $ / shares   $ 17.05            
Debt instrument redemption price, percentage   100.00%            
Carrying value of convertible debt   $ 143,723,000 $ 162,661,000   $ 162,661,000   $ 157,560,000  
Equity component of convertible debt, net of issuance costs and deferred taxes   50,235,000            
Deferred income taxes   $ 13,367,000            
Effective interest rate on convertible notes     11.02%   11.02%      
Convertible notes, unamortized discount and issuance costs     $ 37,339,000   $ 37,339,000      
3.5% Convertible Notes Due 2023 | Minimum                
Debt Instrument [Line Items]                
Common stock price trading days | day   20            
Common stock price consecutive trading days | day   30            
Percentage of common share price over conversion price for conversion   130.00%            
3.5% Convertible Notes Due 2023 | Maximum                
Debt Instrument [Line Items]                
Common stock price trading days | day   5            
Common stock price consecutive trading days | day   5            
Debt instrument redemption price, percentage   98.00%            
Merck Convertible Note                
Debt Instrument [Line Items]                
Aggregate principal amount $ 25,000,000              
Conversion rate upon IPO 0.90              
Interest rate applicable to IPO conversion event 0.05